National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant (HSCT).

NCPE Assessment Process Ongoing
Rapid Review commissioned 03/12/2019
Rapid Review completed 27/01/2020
Rapid Review Outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of polatuzumab vedotin (Polivy®) compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 26/02/2020
Pre-submission consultation with Applicant 31/03/2020
Current status Awaiting HTA submission from Applicant